An open-label, randomized, phase II trial of cetuximab with or without PX-866 in patients with relapsed or metastatic head and neck squamous cell cancer

Trial Profile

An open-label, randomized, phase II trial of cetuximab with or without PX-866 in patients with relapsed or metastatic head and neck squamous cell cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Sonolisib (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Oncothyreon
  • Most Recent Events

    • 30 Sep 2015 The addition of PX-866 to cetuximab failed to improve PFS, ORR, or OS in patients with relapsed or metastatic head and neck squamous cell cancer
    • 29 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top